Welcome to our dedicated page for Fractyl Health news (Ticker: GUTS), a resource for investors and traders seeking the latest updates and insights on Fractyl Health stock.
Fractyl Health, Inc. (Nasdaq: GUTS) is a metabolic therapeutics company focused on new approaches to obesity and type 2 diabetes (T2D), and its news flow centers on clinical data, regulatory progress, and financing activities that support these programs. The company’s updates frequently highlight developments in its Revita® endoscopic therapy and Rejuva® gene therapy platform, along with corporate and capital markets milestones.
News about Revita often covers results from the REMAIN weight maintenance program and the REVEAL‑1 Cohort, which evaluate Revita’s potential to maintain weight loss after GLP‑1 drug discontinuation. Fractyl Health has reported randomized data from the REMAIN‑1 Midpoint Cohort and open‑label data from REVEAL‑1, as well as progress in the REMAIN‑1 Pivotal Cohort and a Germany real‑world registry in inadequately controlled T2D. These releases provide detail on study designs, endpoints, safety observations, and anticipated timelines for additional data and a potential PMA submission.
Coverage of the Rejuva platform includes preclinical results from RJVA‑001 and RJVA‑002, the submission of a Clinical Trial Application module for RJVA‑001 in T2D, and presentations at scientific meetings. The company’s news describes how Rejuva is being developed as an AAV‑based, locally delivered gene therapy approach intended to support long‑term metabolic control.
Investors following GUTS news will also see announcements related to underwritten offerings of common stock, warrant structures and calls, cash runway guidance, board appointments, executive changes, and participation in healthcare conferences. Together, these items provide context on how Fractyl Health is advancing its investigational therapies, managing its capital position, and preparing for potential late‑stage and commercial‑stage activities in metabolic disease.
Fractyl Health (GUTS) presented new preclinical data for its Rejuva RJVA-001 single-administration GLP-1 pancreatic gene therapy candidate. The 13-week study in diet-induced obesity mice showed sustained weight maintenance and blood sugar control, with over 10% of islet cells expressing GLP-1 protein and no safety concerns. The company also announced RJVA-002, a GIP/GLP-1 dual agonist, as its first pancreatic gene therapy candidate for obesity. This AAV9 viral vector expresses human GIP and GLP-1 hormones from a human insulin promoter, targeting both receptors important for blood sugar and weight regulation.
Fractyl Health (Nasdaq: GUTS) presented new analysis from pooled data of Revita® clinical studies showing durable weight loss maintenance for one year. The analysis included 118 participants followed for 48 weeks post-Revita procedure. 90% of patients lost weight at one month, with 84% maintaining weight loss through one year without prescribed diet or lifestyle intervention. The study population had Type 2 Diabetes, with 62% having obesity and 34% being overweight. The Revita procedure, which resurfaces the duodenal lining, was well tolerated with no serious adverse events. The company expects to report pivotal trial data in Q4 2024.
Fractyl Health (Nasdaq: GUTS), a metabolic therapeutics company focusing on obesity and Type 2 Diabetes treatments, has scheduled its third quarter 2024 financial results announcement and business updates for November 12, 2024, at 4:30 p.m. ET. The company will host a live webcast accessible through their investor relations website, with a replay option available after the event.
Fractyl Health (Nasdaq: GUTS) has announced upcoming presentations of weight maintenance data from its Revita and Rejuva platforms at ObesityWeek 2024, scheduled for November 2-6 in San Antonio, Texas. The company will showcase two key presentations:
1. An oral presentation on islet-targeted GLP-1 receptor agonist gene therapy's effects on fat reduction and metabolism improvement in obese mice, scheduled for November 5.
2. A poster presentation demonstrating how duodenal mucosal resurfacing maintains weight loss in metabolic disease, to be presented during the Welcome Reception on November 3.
These presentations highlight Fractyl Health's commitment to developing innovative treatments for obesity and Type 2 Diabetes by addressing their root causes.
Fractyl Health, Inc. (Nasdaq: GUTS), a metabolic therapeutics company focusing on new approaches to treat obesity and Type 2 Diabetes, has announced its participation in Chardan's 8th Annual Genetic Medicines Conference. The company's Co-founder and CEO, Harith Rajagopalan, M.D., Ph.D., will engage in a fireside chat on Tuesday, October 1, 2024, at 9:00 a.m. EDT.
Interested parties can register in advance for the presentation webcast. Following the live session, a replay will be available on the Events page of the Investors section on Fractyl Health's website at https://ir.fractyl.com/. This presentation offers an opportunity for investors and interested individuals to gain insights into Fractyl Health's innovative approaches in metabolic therapeutics.
Fractyl Health (Nasdaq: GUTS), a metabolic therapeutics company focusing on obesity and Type 2 Diabetes treatments, has announced its participation in two upcoming investor conferences. Dr. Harith Rajagopalan, Co-founder and CEO, will represent the company at these events:
1. Morgan Stanley Global Healthcare Conference on 09/06/2024 at 10:45 AM ET (Fireside Chat format)
2. H.C. Wainwright 26th Annual Global Investment Conference on 09/09/2024 at 2:00 PM ET (Company Presentation format)
Webcast replays will be available on the company's investor relations website after the live sessions.
Fractyl Health (GUTS) reported Q2 2024 financial results and provided business updates. Key highlights include:
1. Updated clinical results from German Real-World Registry showing Revita®'s potential for sustained weight loss and blood sugar reduction for at least one year post-treatment.
2. FDA Breakthrough Device designation for Revita in weight maintenance after GLP-1 drug discontinuation.
3. Initiation of REMAIN-1 pivotal study for Revita in weight maintenance, with data readouts expected from Q4 2024.
4. REVITALIZE-1 study on track to report topline data in mid-2025 for an expanded Type 2 Diabetes patient population.
5. Presentation of preclinical data comparing Rejuva® to semaglutide at ADA 2024 Conference.
6. Q2 2024 financial results: R&D expenses $16.8M, SG&A expenses $6.2M, net loss $17.2M, cash position $102.4M.
Fractyl Health (Nasdaq: GUTS) announced promising clinical results from its German Real-World Registry for the Revita® endoscopic procedure. After 12 months, patients experienced:
- A median weight decrease from 111 kg to 97 kg (13% total body weight loss)
- A median HbA1c reduction from 9.6% to 7.2%
- Stable or decreased glucose-lowering medications in 10 out of 11 patients
The study involved 11 hard-to-treat patients with obesity and Type 2 Diabetes. Revita, designed to resurface the duodenal lining, shows potential as a durable weight maintenance solution. The procedure was well-tolerated with no reported adverse safety events.
Fractyl Health (Nasdaq: GUTS), a metabolic therapeutics company focusing on innovative treatments for obesity and type 2 diabetes, has announced it will release its second quarter 2024 financial results and provide business updates on August 14, 2024, at 4:30 p.m. ET. The company will host a live webcast of the conference call, which can be accessed through the 'Events' section of Fractyl's investor relations website. For those unable to attend the live event, an archived version of the webcast will be made available for replay on the company's website.
Fractyl Health (Nasdaq: GUTS) has received FDA Breakthrough Device Designation for its Revita System in weight maintenance for people with obesity who discontinue GLP-1 drugs. Revita is an outpatient endoscopic procedure targeting the duodenal lining to potentially treat root causes of obesity and type 2 diabetes. The designation will enable priority FDA review upon completion of the REMAIN-1 study, with data readouts expected from Q4 2024.
Key points:
- Revita aims to address high discontinuation rates and substantial weight regain after stopping GLP-1 drugs
- Breakthrough status may accelerate development, assessment, and review processes
- Previous studies suggest potential for durable weight maintenance after a single Revita procedure
- Revita is already approved in Germany for T2D treatment